Mirvetuximab soravtansine is under clinical development by ImmunoGen and currently in the Phase I and Phase II in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Mirvetuximab soravtansine’s likelihood of approval (LoA) and phase transition for Triple-Negative Breast Cancer (TNBC) took place on 21 Nov 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway and increased the likelihood of final approval for this indication.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Mirvetuximab soravtansine Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Mirvetuximab soravtansine overview
Mirvetuximab Soravtansine (Elahere, Mirvetuximab Soravtansine-GYNX) is an immunoconjugate consisting of the humanized monoclonal antibody. It is formulated as a solution for the intravenous route of administration, Elahere is indicated for the treatment of adult patients with FRα positive, platinum-resistant epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have received one to three prior systemic treatment regimens.
Mirvetuximab soravtansine (IMGN-853) is under development for the treatment of FR alpha positive solid tumors such as metastatic triple negative breast cancer, platinum-resistant, advanced high-grade epithelial ovarian cancer, advanced-stage ovarian cancer (first line), primary peritoneal cancer and fallopian tube cancer. The drug candidate is administered through intravenous route. It is an antibody-drug conjugate consisting of cytotoxic maytansinoid, DM4, covalently linked to the humanized monoclonal antibody M9346A, which selectively binds to folate receptor 1 (FOLR1). The drug candidate is based on targeted antibody payload (TAP) technology. It was also under development for the treatment of renal cell adenocarcinoma, endometrial cancer and non-small cell lung adenocarcinoma,
ImmunoGen is a clinical-stage biotechnology company that focuses on the development of novel antibody-drug conjugates (ADCs) that facilitate targeted therapies for the treatment of cancer. Its pipeline product candidates include mirvetuximab soravtansine for the treatment of platinum-resistant ovarian cancer; IMGN632 for AML, and blastic plasmacytoid dendritic cell neoplasm (BPDCN); IMGC936, the company’s product candidate for a range of solid tumors; and IMGN151, its next-generation anti-FRa candidate in the preclinical development stage. ImmunoGenorporates its proprietary product development ADC technology to enhance the anticancer activity of monoclonal antibodies. The company has direct operations in the US, Ireland, and the UK. ImmunoGen is headquartered in Waltham, Massachusetts, the US.
Quick View Mirvetuximab soravtansine LOA Data
|Highest Development Stage|